Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report 1 January – 31 March 2024: A challenging start to 2024

First quarter 2024 • Net sales SEK 430.2 million (503.2) • EBITA SEK 17.4 million (41.6) • EBITA margin 4.0 percent (8.3) • EBIT SEK 15.1 million (38.0) • EBIT margin 3.5 percent (7.6) • Profit after financial items SEK 13.5 million (31.3) • Profit for the period SEK 10.5 million (24.5) • Basic earnings per share SEK 1.09 (2.57) • Diluted earnings per share SEK 1.08 (2.55)     Performance measures     Chief Executive Officer’s statement   It was a challenging start on all Nordic markets in 2024, and the first quarter of the year

Giant BidCo publishes a supplement to the offer document for the public cash offer to the shareholders of Byggfakta

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE

La Française des Jeux SA publishes supplement to the offer document in respect of the recommended public offer to the shareholders of Kindred Group plc

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Resolutions of Metso Corporation’s Annual General Meeting

Metso Corporation’s stock exchange release on April 25, 2024, at 3:50 p.m. EESTMetso Corporation’s Annual General Meeting (AGM) was held today, April 25, 2024, in Helsinki. Adoption of the financial statements The AGM adopted the financial statements for the financial year 2023 and resolved to grant the members of the Board of Directors and President and CEO discharge from liability for the financial year January 1 to December 31, 2023. Dividend for 2023 The AGM resolved to approve the Board of Directors’ proposal to pay a dividend of EUR 0.36 per share for the financial year

Škoda Transtech’s engineering and documentation department’s operations in Oulu, Finland will be partially transferred to Etteplan

ETTEPLAN OYJ, Press Release, 25.4.2024 at 3.45 p.m. (EEST) Škoda Transtech’s engineering and documentation department’s operations in Oulu, Finland will be partially transferred to Etteplan Etteplan and Škoda Transtech have agreed on the partial transfer of the engineering and documentation department’s operations of Škoda Transtech in Oulu, Finland to Etteplan. According to the agreement, 21 employees from Škoda Transtech will join Etteplan as existing employees as of May 1, 2024. The agreement is related to Škoda Transtech's concluded change negotiations. Based on the newly

Smoltek publishes a filmed interview with the company’s CTO Farzan Ghavanini

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (“Smoltek”) has published a filmed interview with the company's CTO Farzan Ghavanini. In the interview, Farzan talks, among other things, about the company's latest technical progress for the CNF-MIM technology and what remains to be done in order to be able to compete with today's leading technology for ultra-thin capacitors.Group company Smoltek Semi has recently completed a new technology generation for the company's capacitor technology,

OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs

Stockholm, Sweden – April 25 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the release of a report outlining the opportunity to address critical Unmet Medical Needs in oncology care.Pain remains one of the leading reasons for cancer treatment interuptions and significantly impacts Quality of Life during chemotherapy and radiotherapy. BupiZenge™ is uniquely positioned to help millions of patients, alleviating their oral pain stemming from oral mucositis, a common and debilitating side

Hunter Group ASA - Annual General Meeting held on 25 April 2024

Oslo, 25 April 2024 The Annual General Meeting ("AGM") in Hunter Group ASA (the "Company") took place today on 25 April 2024 at 10:00 hours CET. All resolutions were passed in accordance with the proposals set out in the notice for the AGM. The minutes from the AGM are attached to this announcement.  Contact: Erik A.S. Frydendal, CEO, Ph. +47 957 72 947 E-mail: ef@huntergroup.no Lars M. Brynildsrud, CFO, Ph. +47 932 60 882 E-mail: lb@huntergroup.no This stock exchange announcement is made pursuant to section 5-9 of the Norwegian Securities Trading Act.

NIB and Citadele fund Baltics’ first gene therapy manufacturing facility

The Nordic Investment Bank (NIB), Citadele bank and the Lithuanian biopharmaceutical company UAB Celltechna signed a ten-year financing agreement of EUR 37 million for a gene therapy product facility in Vilnius. NIB will provide a EUR 22.5 million loan, and Citadele will extend a EUR 14.5 million loan for the project.The new Gene Therapy Centre will be the first and so far the only one of its kind in the Baltic countries. It will provide facilities for both research and manufacturing processes, supporting the development of genetic disease treatments. Spanning approximately 8,000 square

IFS announces best Q1 results in company history with 26% increase in ARR YoY and 20% increase in Cloud revenue YoY

New CEO visits 100 customers in first 100 daysLondon, April 25, 2024 – IFS , the global cloud enterprise software company, today announced its financial results for the first quarter ending March 31, 2024. The results reflect the best start to the year in company history – an early victory for new CEO Mark Moffat, who was appointed on January 9th, 2024. Summary of Q1 results:  · Annual Recurring Revenue (ARR) up 26% YoY · Cloud Revenue up 20% YoY · Software Revenue growth up 19% YoY A steadfast customer focus positions IFS as the

Invitation to presentation of Quickbit’s Q3 ‘23/24 interim report

Quickbit will publish its interim report for the period 1 January – 31 March 2024 on Wednesday, 22 May 2024, at 08:00 am CET. On the same day at 11:00 am CET Quickbit will organize a web presentation for investors. Daniel Sonesson, CEO, and Daniel Boettge, CFO, will present and comment on the report and the development. During the presentation there will be time for questions in the web presentation. The presentation will be held in English.   The live webcast will be available at the following link: meet.google.com/cvi-zckx-btp   The presentation and report will be

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") stock exchange announcement on 9 March 2023, in which the Company announced that it had requested Atlas Special Opportunities, LLC ("Atlas") to subscribe and pay for the first tranche of convertible bonds under the Investment Agreement entered into between Atlas and the Company, consisting of 75 convertible bonds. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 500,000 which, pursuant to the bond terms, are convertible into 182,844 new shares in the Company at a

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity

Oslo, 25 April 2024. Lytix Biopharma announces that the Norwegian Medical Products Agency has approved the clinical trial application for a Phase II Neoadjuvant study in early-stage melanoma, a severe form of skin cancer. In this study, Lytix`s lead candidate LTX-315 will be given in combination with another type of immunotherapy before surgery. The study is called NeoLIPA and will be led by Dr. Henrik Jespersen, Head of Melanoma Oncology at Radiumhospitalet (Oslo University Hospital).   “We are very excited to start the NeoLIPA study and investigate the clinical effect of LTX-315 in

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Aquaporin’s shares

Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, Company registration no.: DK28315694 Company announcementNo. 10/2024 Copenhagen, Denmark, April 25, 2024 – Pursuant to the Market Abuse Regulation article 19, Aquaporin A/S (ticker: AQP) (“Aquaporin” or the “Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Aquaporin and persons closely associated with them in Aquaporin’s shares and other financial instruments linked thereto. Reference is made to company announcement no. 09/

Atlas Copco Group awards recognize innovation, marketing, and operational excellence

Nacka, Sweden, April 25, 2024: This year, the Atlas Copco Group awards recognize an innovation to increase energy effectiveness through compressor design, new growth opportunities in Space Simulation Systems through a structured marketing approach as well as a stable, cost effective and increasingly sustainable production process in the Automated Air End manufacturing line.“We say that there is always a better way to do things. The winners of the 2024 Atlas Copco Group awards show that the strive for innovative technology, operational excellence and impressive teamwork means that the motto

Resolutions of Solwers Plc's Annual General Meeting and the Organisational Meeting of the Board of Directors

Solwers Plc, Company Release, April 25, 2024 at 14:15 EEST Solwers Plc's (the "Company") Annual General Meeting was held on Thursday 25 April 2024 in Meeting Park Oasis, Itämerenkatu 14, Helsinki. Resolutions of Solwers Plc's Annual General Meeting Adoption of the financial statements The Annual General Meeting adopted the Company's 2023 financial statements. Resolution on the use of the profit shown on the balance sheet and the distribution of dividend In accordance with the Board of Directors' proposal, the Annual General Meeting resolved to transfer the loss for the

Lundin Gold to Buy Out 100% of Stream Facility to Become Debt Free

VANCOUVER, BC, April 25, 2024 /CNW/ - Lundin Gold Inc. (TSX: LUG; Nasdaq Stockholm: LUG; OTCQX: LUGDF) ("Lundin Gold" or the "Company") is pleased to announce that it has entered into an agreement with Newmont Corporation ("Newmont") to buy out 100% of the balance of the stream credit facility (the “Stream Facility”) and offtake agreement (the “Offtake”) for its 100% owned Fruta del Norte gold mine in Ecuador for total consideration of $330 million. All amounts are in U.S. dollars unless otherwise indicated.   Ron Hochstein, President and CEO commented, “I’m very pleased to announce

Interim report Rejlers AB January – March 2024

January - March · Net sales increased by 10.5% to SEK 1,096.0 million (991.5) · Organic sales growth amounted to 1.0% (9.7), negatively affected by completed restructuring in the fourth quarter of 2023, and one day less compared to the previous year · EBITA increased to SEK 98.3 million (90.1) and the EBITA margin was 9.0% (9.1) · EBITA for 2023 was impacted by integration costs regarding the acquisition of Eurocon and impairment of projects at SEK 10.0 million · Operating profit (EBIT) increased to SEK 83.7 million (70.8), impacted by acquisition expenses of SEK 0.5

Interim Report January–March 2024: Profits significantly down due to derailments on the Iron Ore Line

Operating profit for the first quarter 2024 was down by SEK 3.8 billion and amounted to SEK 1.4 billion. This was a result of the stoppage on the Iron Ore Line, which prevented deliveries from being made. Consequently, operating cash flow was negative during the quarter at SEK -1.5 billion.The derailments on the Iron Ore Line had very major effects on results for the first quarter. Net sales more than halved compared with the same period last year, amounting to MSEK 5,471 (11,955), while operating profit fell to MSEK 1,370 (5,186). The deterioration in earnings meant that cash flow was

Annual report for 2023

Speqta AB's (publ) annual report for 2023 is now published and available on: https://speqta.com/en/investors/financial-reportsThe information was submitted for publication, through the agency of the contact person set out below, on April 25th 2024 at 13:00 CEST.For additional informationJohan Rutgersson, Chairman Speqta ABMobile: +46 (0) 70 815 72 00E-mail: johan@dewell.sewww.speqta.comAbout SpeqtaSpeqta is an Adtech company that enables online advertisers to optimise their marketing through data and AI. The company’s SaaS service BrightBid (including Bidbrain) is a

Nurminen Logistics Plc's Business Review Q1 2024: Good result in a challenging market

Nurminen Logistics Plc    Stock Exchange Release   25 April 2024 at 2.00 pmThis is a summary of Nurminen Logistics' Business Review January-March 2024. The full report is attached to this release and is also available on Nurminen Logistics' website at https://nurminenlogistics.com/investors/publications/  Operating result for the review period increased by 75% to EUR 5.9 million and net sales grew by 40% to EUR 35.2 million.JANUARY-MARCH 2024 SUMMARY · Net sales was EUR 35.2 million (EUR 25.1 million), showing an increase of 40.3%  · EBITDA was EUR 7.3 million (EUR 4.3

There are no items matching the current filter
There are no more items matching the current filter
Back to top